Suchergebnisse - "Alessi, Joao V"

PubPharm (30)

1

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Ricciuti, B. | Lamberti, G. | Puchala, S. | +30

2

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors

enthalten in: Cancer discovery | 2024

von Pecci, F. | Nakazawa, S. | Ricciuti, B. | +38

3

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer

enthalten in: JCO precision oncology | 2024

von Naqash, A. | Floudas, C. | Aber, E. | +21

4

Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors

enthalten in: JCO precision oncology | 2024

von Kerepesi, C. | Abushukair, H. | Ricciuti, B. | +12

ErratumIn: JCO Precis Oncol. 2024 Apr;8:e2400182. - PMID 38579195

5

Transcriptional phenocopies of deleteriousKEAP1mutations dictate survival outcomes in lung cancer treated with immunotherapy

enthalten in: bioRxiv.org | 2023

von Scalera, S. | Ricciuti, B. | Marinelli, D. | +20

6

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Alessi, J. | Wang, X. | Elkrief, A. | +32

7

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

enthalten in: The oncologist | 2023

von Elkrief, A. | Riccuiti, B. | Alessi, J. | +18

ErratumIn: Oncologist. 2024 Jan 5;29(1):e166. - PMID 38000087

8

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

enthalten in: Journal for immunotherapy of cancer | 2023

von Alessi, J. | Price, A. | Richards, A. | +16

ErratumIn: J Immunother Cancer. 2024 Jan 30;12(1):. - PMID 38290770

9

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Thummalapalli, R. | Ricciuti, B. | Bandlamudi, C. | +25

10

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden

enthalten in: Cancer cell | 2023

von Zhu, M. | Kim, J. | Deng, Q. | +14